Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization

Yunosuke Nishihara, Shinichi Aishima, Yohsuke Kuroda, Tomohiro Iguchi, Kenichi Taguchi, Yoshiki Asayama, Akinobu Taketomi, Naoko Kinukawa, Hiroshi Honda, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Aim: Transcatheter arterial chemoembolization (TACE) is now the mainstay of treatment for non-curative hepatocellular carcinoma (HCC), and hoped to have chemotherapeutic and ischemic effects; however, the histopathological changes of HCC caused by TACE have not been sufficiently discussed so far. We aimed to assess the morphological and immunohistochemical features of HCC treated with TACE by immunostaining cytokeratin (CK) 7, CK14, CK19 and vimentin, and to correlate these data with observed clinicopathological characteristics. Methods: Eighty cases of surgically resected HCC with preoperative TACE and 146 cases of HCC resected without TACE as a control were analyzed. Results: The incidences of intrahepatic metastasis, poorly differentiated histology, multinucleated giant cells, mitotic figures and cytoplasmic inclusion bodies in the TACE group were significantly higher than those in the non-TACE group. The TACE group showed reactivity for CK7 in 56.3% (45/80) of patients, CK14 in 12.5% (10/80), CK19 in 23.8% (19/80) and vimentin in 6.3% (5/80) of patients. CK19 expression in the TACE group was significantly higher than in the non-TACE group (P = 0.0423). There was no correlation between immunoreactivity and the number of times TACE was carried out, but the expression of CK19 and vimentin in the massive necrotic group was higher than that in the mild necrotic group (P = 0.0197, P = 0.0229, respectively). Only TACE was an independent determinant of CK19 expression in all cases by multivariate analysis. Conclusions: These results suggest that preoperative TACE may have an impact on the biliary phenotype of HCC. Some post-therapeutic HCC patients might develop HCC with a biliary phenotype indicating more aggressive malignancies.

Original languageEnglish
Pages (from-to)1860-1868
Number of pages9
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume23
Issue number12
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Hepatocellular Carcinoma
Phenotype
Vimentin
Inclusion Bodies
Keratin-7
Giant Cells
Histology
Multivariate Analysis
Neoplasm Metastasis
Incidence
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization. / Nishihara, Yunosuke; Aishima, Shinichi; Kuroda, Yohsuke; Iguchi, Tomohiro; Taguchi, Kenichi; Asayama, Yoshiki; Taketomi, Akinobu; Kinukawa, Naoko; Honda, Hiroshi; Tsuneyoshi, Masazumi.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 23, No. 12, 01.01.2008, p. 1860-1868.

Research output: Contribution to journalArticle

Nishihara, Y, Aishima, S, Kuroda, Y, Iguchi, T, Taguchi, K, Asayama, Y, Taketomi, A, Kinukawa, N, Honda, H & Tsuneyoshi, M 2008, 'Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization', Journal of Gastroenterology and Hepatology (Australia), vol. 23, no. 12, pp. 1860-1868. https://doi.org/10.1111/j.1440-1746.2008.05601.x
Nishihara, Yunosuke ; Aishima, Shinichi ; Kuroda, Yohsuke ; Iguchi, Tomohiro ; Taguchi, Kenichi ; Asayama, Yoshiki ; Taketomi, Akinobu ; Kinukawa, Naoko ; Honda, Hiroshi ; Tsuneyoshi, Masazumi. / Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization. In: Journal of Gastroenterology and Hepatology (Australia). 2008 ; Vol. 23, No. 12. pp. 1860-1868.
@article{5736a90b7a014fcdb6711595d6a61658,
title = "Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization",
abstract = "Background and Aim: Transcatheter arterial chemoembolization (TACE) is now the mainstay of treatment for non-curative hepatocellular carcinoma (HCC), and hoped to have chemotherapeutic and ischemic effects; however, the histopathological changes of HCC caused by TACE have not been sufficiently discussed so far. We aimed to assess the morphological and immunohistochemical features of HCC treated with TACE by immunostaining cytokeratin (CK) 7, CK14, CK19 and vimentin, and to correlate these data with observed clinicopathological characteristics. Methods: Eighty cases of surgically resected HCC with preoperative TACE and 146 cases of HCC resected without TACE as a control were analyzed. Results: The incidences of intrahepatic metastasis, poorly differentiated histology, multinucleated giant cells, mitotic figures and cytoplasmic inclusion bodies in the TACE group were significantly higher than those in the non-TACE group. The TACE group showed reactivity for CK7 in 56.3{\%} (45/80) of patients, CK14 in 12.5{\%} (10/80), CK19 in 23.8{\%} (19/80) and vimentin in 6.3{\%} (5/80) of patients. CK19 expression in the TACE group was significantly higher than in the non-TACE group (P = 0.0423). There was no correlation between immunoreactivity and the number of times TACE was carried out, but the expression of CK19 and vimentin in the massive necrotic group was higher than that in the mild necrotic group (P = 0.0197, P = 0.0229, respectively). Only TACE was an independent determinant of CK19 expression in all cases by multivariate analysis. Conclusions: These results suggest that preoperative TACE may have an impact on the biliary phenotype of HCC. Some post-therapeutic HCC patients might develop HCC with a biliary phenotype indicating more aggressive malignancies.",
author = "Yunosuke Nishihara and Shinichi Aishima and Yohsuke Kuroda and Tomohiro Iguchi and Kenichi Taguchi and Yoshiki Asayama and Akinobu Taketomi and Naoko Kinukawa and Hiroshi Honda and Masazumi Tsuneyoshi",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2008.05601.x",
language = "English",
volume = "23",
pages = "1860--1868",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization

AU - Nishihara, Yunosuke

AU - Aishima, Shinichi

AU - Kuroda, Yohsuke

AU - Iguchi, Tomohiro

AU - Taguchi, Kenichi

AU - Asayama, Yoshiki

AU - Taketomi, Akinobu

AU - Kinukawa, Naoko

AU - Honda, Hiroshi

AU - Tsuneyoshi, Masazumi

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background and Aim: Transcatheter arterial chemoembolization (TACE) is now the mainstay of treatment for non-curative hepatocellular carcinoma (HCC), and hoped to have chemotherapeutic and ischemic effects; however, the histopathological changes of HCC caused by TACE have not been sufficiently discussed so far. We aimed to assess the morphological and immunohistochemical features of HCC treated with TACE by immunostaining cytokeratin (CK) 7, CK14, CK19 and vimentin, and to correlate these data with observed clinicopathological characteristics. Methods: Eighty cases of surgically resected HCC with preoperative TACE and 146 cases of HCC resected without TACE as a control were analyzed. Results: The incidences of intrahepatic metastasis, poorly differentiated histology, multinucleated giant cells, mitotic figures and cytoplasmic inclusion bodies in the TACE group were significantly higher than those in the non-TACE group. The TACE group showed reactivity for CK7 in 56.3% (45/80) of patients, CK14 in 12.5% (10/80), CK19 in 23.8% (19/80) and vimentin in 6.3% (5/80) of patients. CK19 expression in the TACE group was significantly higher than in the non-TACE group (P = 0.0423). There was no correlation between immunoreactivity and the number of times TACE was carried out, but the expression of CK19 and vimentin in the massive necrotic group was higher than that in the mild necrotic group (P = 0.0197, P = 0.0229, respectively). Only TACE was an independent determinant of CK19 expression in all cases by multivariate analysis. Conclusions: These results suggest that preoperative TACE may have an impact on the biliary phenotype of HCC. Some post-therapeutic HCC patients might develop HCC with a biliary phenotype indicating more aggressive malignancies.

AB - Background and Aim: Transcatheter arterial chemoembolization (TACE) is now the mainstay of treatment for non-curative hepatocellular carcinoma (HCC), and hoped to have chemotherapeutic and ischemic effects; however, the histopathological changes of HCC caused by TACE have not been sufficiently discussed so far. We aimed to assess the morphological and immunohistochemical features of HCC treated with TACE by immunostaining cytokeratin (CK) 7, CK14, CK19 and vimentin, and to correlate these data with observed clinicopathological characteristics. Methods: Eighty cases of surgically resected HCC with preoperative TACE and 146 cases of HCC resected without TACE as a control were analyzed. Results: The incidences of intrahepatic metastasis, poorly differentiated histology, multinucleated giant cells, mitotic figures and cytoplasmic inclusion bodies in the TACE group were significantly higher than those in the non-TACE group. The TACE group showed reactivity for CK7 in 56.3% (45/80) of patients, CK14 in 12.5% (10/80), CK19 in 23.8% (19/80) and vimentin in 6.3% (5/80) of patients. CK19 expression in the TACE group was significantly higher than in the non-TACE group (P = 0.0423). There was no correlation between immunoreactivity and the number of times TACE was carried out, but the expression of CK19 and vimentin in the massive necrotic group was higher than that in the mild necrotic group (P = 0.0197, P = 0.0229, respectively). Only TACE was an independent determinant of CK19 expression in all cases by multivariate analysis. Conclusions: These results suggest that preoperative TACE may have an impact on the biliary phenotype of HCC. Some post-therapeutic HCC patients might develop HCC with a biliary phenotype indicating more aggressive malignancies.

UR - http://www.scopus.com/inward/record.url?scp=57049174430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049174430&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2008.05601.x

DO - 10.1111/j.1440-1746.2008.05601.x

M3 - Article

VL - 23

SP - 1860

EP - 1868

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 12

ER -